Will Crowd Sourcing Help AstraZeneca plc And GlaxoSmithKline plc Rekindle Growth?

 AstraZeneca plc (LON:AZN) and GlaxoSmithKline plc (LON: GSK) are pooling their resources to try and restart growth.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s no secret that AstraZeneca (LSE: AZN) and GlaxoSmithKline (LSE: GSK) are struggling to grow. Both companies are trying to offset declining sales of legacy drugs by branching out and reinvigorating their development pipeline, which is taking time. 

However, the two groups are now, along with peers from around the world, embarking on a great crowd-sourcing experiment to try rekindle old flames. 

Working together

Developing new drugs is a hit or miss business. Treatments that have taken years to develop can fall at the last hurdle, or be pulled because they’re not economically viable. In most cases, development of these treatments has sucked in millions of pounds in research and development spending, to no avail. What’s more, pharma companies closely guard their research — so if a treatment fails, there’s usually no second attempt by another party. 

But now, seven of the world’s leading pharma companies, including Astra and Glaxo, are getting together to pool their resources and put together a library of 68 compounds that have failed to make it to market. 

The theory is that by pooling resources, a use for these compounds will be found. In other words, someone somewhere will have the key to unlock the puzzle, finish development and commercialise the product. The compound library will help the companies share research and leverage their experience in certain fields. 

This is part of a huge drive by drug makers to increase productivity from R&D departments. Indeed, Astra and Glaxo are both looking to move away from the ‘blockbuster drug’ mentality, whereby one main drug makes up the vast majority of company sales. Instead, they are trying to develop a portfolio of key treatments.

Not only will the compound library lead to a wider variety of treatments being discovered but it should also encourage R&D, as the vast majority of work on existing compounds within the library will have been done already. It’s much easier to adapt a compound that has already been created, rather than create one yourself!

In progress

The compound library is already attracting plenty of attention and follows a deal earlier this year between The Medical Research Council (MRC) and Astra. This particular deal saw Astra make 22 of its chemical compounds available free-of-charge to scientists.

Astra had already begun testing these compounds but had put their development on hold. Scientists from the MRC will work on the compounds and carry out medical research, leaving Astra’s R&D team free to work on other things. 

As of yet, it’s unclear which party will commercialise the products if the research yields results, although the MRC is unlikely to chase development, which leaves Astra as the only viable alternative. 

Long-term outlook

Astra’a and Glaxo’s move away from the blockbuster drug mentality, towards a more co-operative and open business model, is great news for the two companies and sector in general. 

Sharing technology will increase the change of a new product being discovered and will free up some research teams. This should boost sales growth over the long term. From an investor’s point of view, this is extremely important. You see, developing a product for several years, spending millions and tying up a research team is inefficient. So, sharing resources reduces the risk that money and time will be wasted. What’s more, Glaxo and Astra will both be able to cut costs, as they share resources, boosting margins.  

Then there’s the issue of increasing sales. New products, discovered through collaboration can be sold, offsetting the decline in legacy sales. All in all, there are multiple financial benefits to be had from this deal and it should boost Astra’s and Glaxo’s growth sales, and earnings growth going forward. Shareholders will benefit through higher earnings and even dividends.  

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »